Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

19:10 EDT 1st May 2016 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 5,900+

Extremely Relevant

Galectin nets $9.2mm through registered direct offering

Galectin Therapeutics Inc. netted $9.2mm through a registered direct offering of 4.76mm common shares at $2.06 (a 17% discount); buyers also received five-year warrants to purchase 3.6mm shares at $2.50. Roth Capital was the placement agent. The company is developing galectin protein-based treatments for fibrotic liver diseases, cancer, and psoriasis.


Relevant

Galectin appoints Dr. Marc Rubin as chairman

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of […]

Galectin-3 And Cardiac Troponins Reference Values Determined

Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...


Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering

NORCROSS, Ga., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share ...

Galectin Therapeutics Selected to Present at Cavendish Global Health Impact Forum

NORCROSS, Ga., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th to October 28th at The Cleveland Clinic in Cleveland, Ohio....

Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update

NORCROSS, Ga., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months ended September 30, 2015 and provided a business update. These results are included in the Company's Quarterly Report on Form 10-Q, which has been f...

Galectin Therapeutics' (GALT) CEO Peter Traber on Q4 2015 Results - Earnings Call Transcript

Osteoarthritis: Galectin-1 damages cartilage via inflammation

Galectin-3 inhibition prevents adipose tissue remodelling in obesity

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test

WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid...

Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting

NORCROSS, Ga., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that preclinical research from a study led by Stefanie Linch, Ph.D. in the laboratory of tumor immunology expert William L. Redmond, Ph.D. of the Providence Cancer Center's Earle A. Chiles Research I...

Kesios Therapeutics raises £19 million; names executives

Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics…

D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2015-09-11. This 25-page report is available in PDF from $300. Table of Contents Section 1 - About the Company D. Western Therapeutics Institute, Inc. - Key Information D. Western Therapeutics Institute, In...

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BTP-114, for which the FDA has accepted an Investigational New Drug (IND) application to begin clinical evaluation in cancer patients. Placon was spun out from Blend Therapeutics (now Tarveda Therapeuti...

PTC Therapeutics, MGH ally in R&D of rare disease therapeutics

PTC Therapeutics Inc. and Massachusetts General Hospital are together developing treatments for rare, genetic disorders, including the fatal sensory and autonomic neuropathy known as familial dysautonomia (FD), or Riley-Day syndrome.

Living Therapeutics

An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments

Tarveda spins platinum-based drug assets out into newco Placon Therapeutics

Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.

Intensity Therapeutics Inc.

Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masses and then prime the immune system to seek out metastases.

AstraZeneca to collaborate with Moderna Therapeutics to develop mRNA therapeutics

Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…

Pluristem, United Therapeutics end licensing agreement to develop PAH treatment

Israeli cell therapy specialist Pluristem Therapeutics said it has received a notice from United Therapeutics…

Digital Therapeutics Have Huge Promise And They Are Real Today

Digital therapeutics have made surprising progress. This is good news, because digital therapeutics are typically cheap, and they have shown impressive ability to change behavior, one of the most important challenges in healthcare.

Bayer, CRISPR Therapeutics AG to Collaborate on Genetic Disease Research

Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering ex...

Pear Therapeutics raises $20M for digital therapeutics portfolio aimed at substance abuse, schizophrenia

Pear Therapeutics received equity finance backing from a group of investors with 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners leading the round.

Knight licenses three Antibe compounds

Antibe Therapeutics Inc. signed a long-term license and distribution agreement with fellow Canadian therapeutics developer Knight Therapeutics Inc. for three of Antibe’s prescription anti-inflammatory and pain drug candidates.


Quick Search
Advertisement
 

News Quicklinks